541 related articles for article (PubMed ID: 15199474)
1. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
2. P2y(12), a new platelet ADP receptor, target of clopidogrel.
Savi P; Labouret C; Delesque N; Guette F; Lupker J; Herbert JM
Biochem Biophys Res Commun; 2001 May; 283(2):379-83. PubMed ID: 11327712
[TBL] [Abstract][Full Text] [Related]
3. Identification and biological activity of the active metabolite of clopidogrel.
Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
5. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
6. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
8. Platelet P2 receptors: old and new targets for antithrombotic drugs.
Cattaneo M
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
[TBL] [Abstract][Full Text] [Related]
9. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
Bouman HJ; Parlak E; van Werkum JW; Breet NJ; ten Cate H; Hackeng CM; ten Berg JM; Taubert D
J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.
Zhan C; Yang J; Dong XC; Wang YL
J Mol Graph Model; 2007 Jul; 26(1):20-31. PubMed ID: 17110146
[TBL] [Abstract][Full Text] [Related]
13. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
Foster CJ; Prosser DM; Agans JM; Zhai Y; Smith MD; Lachowicz JE; Zhang FL; Gustafson E; Monsma FJ; Wiekowski MT; Abbondanzo SJ; Cook DN; Bayne ML; Lira SA; Chintala MS
J Clin Invest; 2001 Jun; 107(12):1591-8. PubMed ID: 11413167
[TBL] [Abstract][Full Text] [Related]
14. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
15. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
[TBL] [Abstract][Full Text] [Related]
16. P2Y receptor antagonists in thrombosis.
Boeynaems JM; van Giezen H; Savi P; Herbert JM
Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
[TBL] [Abstract][Full Text] [Related]
17. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
[TBL] [Abstract][Full Text] [Related]
18. The P2 receptors in platelet function.
Hechler B; Cattaneo M; Gachet C
Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
[TBL] [Abstract][Full Text] [Related]
20. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
